Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Namrata Bhatnagar"'
Autor:
Andrew L. Kung, Amanda L. Christie, Nathan Moore, Stacey M. Frumm, Nathanael S. Gray, Rani E. George, Lauren Drake, Kenneth N. Ross, Louis Chesler, Namrata Bhatnagar, Anna M. Azarova, Takaomi Sanda, Qinsong S. Liu, Kimberly Stegmaier
Publikováno v:
Oncotarget
Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::916b16c191ef91fb72ee753b41094bf7
https://doi.org/10.18632/oncotarget.2372
https://doi.org/10.18632/oncotarget.2372
Autor:
Nathanael S. Gray, David Debruyne, Namrata Bhatnagar, Nathan Moore, Rani E. George, Cheung Nk, William Luther, Bandana Sharma
Publikováno v:
Oncogene
The crizotinib-resistant ALK(F1174L) mutation arises de novo in neuroblastoma (NB) and is acquired in ALK translocation-driven cancers, lending impetus to the development of novel anaplastic lymphoma kinase (ALK) inhibitors with different modes of ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::615d49597bc0c4d1fdb1f411b4188b05
https://pubmed.ncbi.nlm.nih.gov/26616860
https://pubmed.ncbi.nlm.nih.gov/26616860
Publikováno v:
The FASEB Journal. 23
Butyrate is an inhibitor of histone deacetylase (HDAC) and has been extensively evaluated as a chemoprevention agent for colon cancer. We recently showed that mutations in the adenomatous polyposis coli (APC) gene confer resistance to HDAC inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9bafbd47cae1d5cb2e501fdd821c902
https://doi.org/10.1096/fasebj.23.1_supplement.940.4
https://doi.org/10.1096/fasebj.23.1_supplement.940.4
Autor:
Lauren Olsen-Drake, Stacey M. Frumm, Amanda L. Christie, Kimberley Stegmaier, Kenneth N. Ross, James G. Christensen, Nathanael S. Gray, Takaomi Sanda, Andrew L. Kung, Rani E. George, Qingsong Liu, Namrata Bhatnagar, Anna M. Azarova, Scott J. Rodig
Publikováno v:
Cancer Research. 72:2935-2935
Mutations in the anaplastic lymphoma kinase (ALK) receptor represent an important therapeutic target in neuroblastoma. The most frequently occurring somatic mutation, ALK F1174L, is sensitive to the ALK inhibitor crizotinib only at higher doses in vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9015a408eb09aee05702bd8b13692d0d
https://doi.org/10.1158/1538-7445.am2012-2935
https://doi.org/10.1158/1538-7445.am2012-2935
Publikováno v:
Cell Death & Disease
Advanced prostate cancers are known to acquire not only invasive capabilities but also significant resistance to chemotherapy-induced apoptosis. To understand how microRNAs (miRNAs) may contribute to prostate cancer resistance to apoptosis, we compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e6bc06edb97b102b8c790812e1a86c2
http://europepmc.org/articles/PMC3004480
http://europepmc.org/articles/PMC3004480
Autor:
Yann Jamin, De-Sheng Pei, Antonio R. Perez-Atayde, Takaomi Sanda, Wenchao Wang, Louis Chesler, Albert Hallsworth, William Luther, Bandana Sharma, Bengt Hallberg, Namrata Bhatnagar, Nai-Kong V. Cheung, Scott J. Rodig, Andrew D.J. Pearson, Winston R. Vetharoy, Simon P. Robinson, Qingsong Liu, Teeara Berry, Zai Ahmad, Karen Barker, Rani E. George, Evon Poon, Florence I. Raynaud, Lisa A. Moreau, Suzanne A. Eccles, Hannah Webber, Nathanael S. Gray
Publikováno v:
Cancer Cell. (1):117-130
The ALK(F1174L) mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model overexpressing ALK(F1174L) in the neural crest. Compared to ALK(F1174L)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3da74eee605c7c04110508b24623df07
Autor:
Ding, Zhenhua, Jian, Sun, Peng, Xuebiao, Liu, Yimin, Wang, Jianyu, Zheng, Li, Ou, Chengshan, Wang, Yinghui, Zeng, Weixia, Zhou, Meijuan, Namrata, Bhatnagar.
Publikováno v:
Medicine; August 2015, Vol. 94 Issue: 33 pe1327-e1327, 1p